Formulation and Evaluation of Orodispersible Tablets of Galantamine Hydrochloride for Effective Treatment of Alzheimer

Alzheimer’s disease is a progressive neurodegenerative disorder characterized by cognitive decline, memory loss, and impaired daily functioning. Alzheimer's disease is commonly managed using cholinesterase inhibitors such as Galantamine Hydrochloride, which enhances cholinergic transmission in the brain by inhibiting acetylcholinesterase enzyme activity.
The present study was aimed at the formulation and evaluation of Orodispersible Tablets (ODTs) of Galantamine Hydrochloride to improve patient compliance, particularly in geriatric patients who experience difficulty in swallowing conventional tablets. ODTs were prepared by direct compression method using suitable superdisintegrants and excipients. Pre-compression parameters such as angle of repose, bulk density, tapped density, Carr’s index, and Hausner ratio were evaluated to assess flow properties of the powder blend.
Post-compression evaluation included hardness, thickness, weight variation, friability, disintegration time, wetting time, drug content, and in-vitro dissolution studies. All formulated batches complied with pharmacopoeial limits. The optimized batch showed acceptable mechanical strength, rapid disintegration, and satisfactory drug release profile.
The results indicated that the developed Orodispersible Tablets of Galantamine Hydrochloride can provide rapid onset of action and improved patient convenience, making them a promising alternative to conventional dosage forms for the effective management of Alzheimer’s disease.

Galantamine Hydrochloride , Alzheimer's disease, Orodispersible Tablets (ODT)Direct Compression, Superdisintegrants ,In-vitro Dissolution Study, Drug Release Kinetics Patient Compliance

1. Sharma P, Verma S, Singh J. Development of extended-release multiparticulate pellets incorporated into orodispersible tablets using Eudragit NE 30D. J Pharm Innov. 2024;19(2):101-110. [Google Scholar] [Crossref]

2. Patel J, Shah T, Amin A. Compression of extended-release coated pellets into orodispersible tablets using cushioning excipients. Int J Pharm Sci. 2023;15(1):88-96. [Google Scholar] [Crossref]

3. Singh BN, Kumar R, Mishra D. Effect of coating thickness and curing temperature on drug release from Galantamine extended-release pellets. Pharm Dev Technol. 2022;27(4):455-462. [Google Scholar] [Crossref]

4. Verma RK, Garg S. Evaluation of Eudragit NE 30D for pH-independent sustained drug delivery. Drug Dev Ind Pharm. 2021;47(3):389-397. [Google Scholar] [Crossref]

5. Rajoriya V, Gupta R. Folate functionalized nanostructured lipid carriers of paclitaxel for site specific A549 lung adenocarcinoma targeting. BioNanoSci. 2025;15:503. [Google Scholar] [Crossref]

6. Kumar A, Sharma PK, Singh R. Multiparticulate drug delivery systems: Advantages over single-unit dosage forms. J Drug Deliv Sci Technol. 2020;55:101443. [Google Scholar] [Crossref]

7. Gupta DK, Bajpai M, Chatterjee DP. Orodispersible tablets for geriatric patients: Formulation and patient compliance. Asian J Pharm Sci. 2019;14(2):145-153. [Google Scholar] [Crossref]

8. Rao NG, Kotta S, Suresh P. Optimization of Wurster coating process for extended-release pellets. Int J Pharm Investig. 2018;8(1):1-8. [Google Scholar] [Crossref]

9. Mishra B, Panigrahi D, Dey S. Compression behavior of polymer coated pellets using cushioning agents. AAPS PharmSciTech. 2017;18(6):2153-2162. [Google Scholar] [Crossref]

10. Khan GM, Zhu JB. Formulation of Galantamine extended-release pellets using acrylic polymers. Drug Dev Ind Pharm. 2016;42(2):201-210. [Google Scholar] [Crossref]

11. Iyer SS, Shivanand P, Suresh S. Role of superdisintegrants in orodispersible tablet formulation. Int J Pharm Sci Rev Res. 2015;30(1):196-201. [Google Scholar] [Crossref]

12. Desai PM, Liew CV, Heng PW. Review of compression and taste masking of multiparticulate systems. Int J Pharm. 2014;461(1-2):1-10. [Google Scholar] [Crossref]

13. Mehta KA, Shah NH, Malick AW. Sustained-release cholinesterase inhibitor formulations for Alzheimer’s therapy. J Control Release. 2013;167(2):123-130. [Google Scholar] [Crossref]

14. Joshi M, Patel D, Desai T. Compression of coated pellets: Effect of polymer flexibility. AAPS PharmSciTech. 2012;13(3):780-788. [Google Scholar] [Crossref]

15. Reddy LH, Murthy RS. Role of particle size and coating uniformity in multiparticulate drug delivery. Int J Pharm. 2011;418(1):1-8. [Google Scholar] [Crossref]

16. Kulkarni AS, Deokar GS, Bhalerao SS. Multiparticulate extended-release drug delivery systems. Int J Pharm Sci Rev Res. 2010;5(2):18-24. [Google Scholar] [Crossref]

17. Shah NH, Malick AW, Infeld MH. Diffusion controlled polymer coated drug delivery systems. J Control Release. 2009;134(3):187-195. [Google Scholar] [Crossref]

18. Saxena V, Pathak K. Orodispersible tablets in Alzheimer’s therapy: Formulation and evaluation. Drug Dev Ind Pharm. 2008;34(7):722-728. [Google Scholar] [Crossref]

19. Rajoriya V, Gupta R, Vengurlekar S, Jain SK. Folate conjugated nano-lipid construct of paclitaxel for site-specific lung squamous carcinoma targeting. Int J Pharm. 2025;672:125312. [Google Scholar] [Crossref]

20. Bhattacharya S, Sen S. Polymer coated multiparticulate systems for near zero-order drug release. AAPS PharmSciTech. 2007;8(3):E1-E6. [Google Scholar] [Crossref]

21. Choudhary PK, Pawar AP. Effect of plasticizers on polymer film flexibility and drug release. Int J Pharm. 2006;321(1-2):10-17. [Google Scholar] [Crossref]

22. Rajoriya V, Gupta R. Folate anchored nanostructured lipid carrier for lung A549 adenocarcinoma cell targeting. J Neonatal Surg. 2025;14(32S):3272-3280. [Google Scholar] [Crossref]

23. Tariot PN, Solomon PR, Morris JC. Galantamine in mild to moderate Alzheimer’s disease: Clinical efficacy study. Neurology. 2005;65(12):1952-1960. [Google Scholar] [Crossref]

24. Robinson JR, Lee VHL. Influence of coating thickness on diffusion-controlled drug release. J Pharm Sci. 2004;93(6):1534-1543. [Google Scholar] [Crossref]

25. Ghebre-Sellassie I. Multiparticulate oral drug delivery systems. Marcel Dekker; 2003. [Google Scholar] [Crossref]

26. Rajoriya V, Rajoriya V, Gupta R, Gupta S, Jain SK. Analyzing terpenes' role in cancer treatment. IGI Global Scientific Publishing; 2025. p. 87–106. [Google Scholar] [Crossref]

27. Manish Tripathi, Ajay Singh Thakur, Prachi Tripathi, Vaibhav Rajoriya, Ramdarshan Parashar, Yogesh Sharma, Deepak Koshti (2026). Formulation, Characterization and In-Vitro Evaluation of Curcumin Loaded Liposome for Colon Drug delivery. , 10(12), https://doi.org/10.51584/IJRIAS.2025.10120077. [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy
• The Science of Sustained-Release Medications
• Development of Proteomics in Clinical Medicine
• Advances on Quinoline Derivatives: A Review of Synthesis and Biological Activities